Overview
On 28th January 2025, Zimmer Biomet Holdings, Inc., a leading global medical technology company, has announced a definitive agreement to acquire Paragon 28, Inc., a specialist in foot and ankle orthopedic devices, in a $1.2 billion transaction. The acquisition will be executed through an upfront cash payment of $13.00 per share, representing an equity value of $1.1 billion, along with an additional contingent value right (CVR) of up to $1.00 per share. The CVR will be payable if Paragon 28 achieves net sales between $346 million and $361 million by 2026.
The acquisition has been unanimously approved by the boards of both companies and is expected to close in the first half of 2025, pending regulatory and shareholder approvals. Zimmer Biomet plans to finance the deal through a combination of cash reserves and debt financing while maintaining a strong balance sheet.
Key Highlights of the Acquisition
- Enhances Zimmer Biomet’s Foot & Ankle Portfolio: This acquisition strengthens and expands Zimmer Biomet’s foot and ankle orthopedic segment, a $5 billion industry growing at high single digits. Paragon 28’s innovative technology and specialized implants will complement Zimmer Biomet’s existing fracture, trauma, and joint replacement offerings.
- Strong Revenue Growth Potential: Paragon 28 has projected net revenue of $255.9–$256.2 million for 2024, representing a growth rate of over 18% year-over-year. The deal is expected to immediately accelerate Zimmer Biomet’s top-line revenue growth.
- Financial Impact: The transaction is expected to be 3% dilutive to Zimmer Biomet’s adjusted earnings per share (EPS) in 2025, 1% dilutive in 2026, and will become accretive within 24 months post-close. Despite initial dilution, the acquisition is positioned as a long-term value driver for Zimmer Biomet.
- Accelerates U.S. and International Expansion: Zimmer Biomet will leverage Paragon 28’s expansive portfolio and existing global infrastructure to drive faster adoption of foot and ankle surgical solutions across key markets, boosting its presence in both domestic and international orthopedic sectors.
- Expansion into the Ambulatory Surgery Center (ASC) Market: The deal strengthens Zimmer Biomet’s penetration into the fast-growing ASC space, where minimally invasive orthopedic procedures are becoming increasingly common. This market segment is a key area of growth for medical device companies, as ASCs offer cost-effective alternatives to traditional hospital-based surgeries.
For Source: Click Here
